Jeremy S. McComish
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jeremy S. McComish has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Louisa Bell
RCH Melbourne: The Royal Children's Hospital Melbourne, Melbourne, Australia
2 shared publicationsChristian P. Brizard
Cardiac Surgery Unit, Royal Children's Hospital, Melbourne, Australia
1 shared publicationChristopher Hogan
Austin Health, Melbourne, Australia
1 shared publication- Christopher Hogan
Austin Pathology, Austin Health, Melbourne, Australia
1 shared publication Daniela Zantomio
Austin Health, Melbourne, Australia
1 shared publication- Daniela Zantomio
Clinical Haematology Austin Health Melbourne Australia
1 shared publication
Latest Publications
- 23 June 2026
- Published by Elsevier in Transplant Immunology
- Vol. 97, 102412
HLA selected red cell transfusions to prevent HLA sensitisation: a prospective, double-blinded, randomised controlled trial
- 23 June 2026
- Published by Elsevier in Transplant Immunology
- Vol. 97, 102412
HLA selected red cell transfusions to prevent HLA sensitisation: a prospective, double-blinded, randomised controlled trial
- 19 June 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (10) , 3671
Response to: ‘Do transfusion-related HLA antibodies always indicate clinically relevant sensitisation?’
- 19 June 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (10) , 3671
Response to: ‘Do transfusion-related HLA antibodies always indicate clinically relevant sensitisation?’
- Open Access
- 20 February 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (7) , 2157-2167
De novo HLA antibodies after blood transfusion and/or kidney transplant in children with kidney disease
Background This study assessed de novo human leukocyte antigen (HLA) antibodies associated with blood transfusions in a paediatric kidney transplantation cohort, associated risk factors and outcomes. Methods Patients with kidney disease at Royal Children’s Hospital (Melbourne, Australia) who were transfused and/or received a kidney transplant between 2000 and 2018 were included. HLA antibody results from pre- and post-transfusion serum specimens, blood donor typing (where available) and clinical and laboratory data were collected. A control group comprised non-transfused patients from the same cohort. The primary outcome was the incidence proportion of de novo blood donor specific HLA antibodies (bDSA). Secondary outcomes included risk factors, including eplet mismatches with the blood donor, kidney donor and both. Results Screening identified 123 transfused and 63 non-transfused patients, with 34 and 28, respectively, included. Transfused patients were younger. At mean fluorescence intensity (MFI) cutoff 500, 36.7% of transfused patients developed de novo HLA class 1 bDSA and 23.3% de novo HLA class 2 bDSA. Overall, de novo HLA class 1 and class 2 antibodies were non-significantly higher in the transfused group (64.7%/55.9%) than in the non-transfused group (46.4% for both, p = 0.200 and p = 0.610, respectively). Risk factors identified included younger age (p < 0.05) and rhesus factor D (RhD) negative status (p = 0.021). The number of shared eplet mismatches was associated with corresponding de novo HLA antibodies (p = 0.02). Conclusions Blood transfusion can be associated with bDSA in paediatric kidney disease, especially with shared blood and kidney donor mismatches. Strategies to avoid sensitisation, such as HLA selection of blood donors, may reduce this risk. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 20 February 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (7) , 2157-2167
Open AccessDe novo HLA antibodies after blood transfusion and/or kidney transplant in children with kidney disease
Background This study assessed de novo human leukocyte antigen (HLA) antibodies associated with blood transfusions in a paediatric kidney transplantation cohort, associated risk factors and outcomes. Methods Patients with kidney disease at Royal Children’s Hospital (Melbourne, Australia) who were transfused and/or received a kidney transplant between 2000 and 2018 were included. HLA antibody results from pre- and post-transfusion serum specimens, blood donor typing (where available) and clinical and laboratory data were collected. A control group comprised non-transfused patients from the same cohort. The primary outcome was the incidence proportion of de novo blood donor specific HLA antibodies (bDSA). Secondary outcomes included risk factors, including eplet mismatches with the blood donor, kidney donor and both. Results Screening identified 123 transfused and 63 non-transfused patients, with 34 and 28, respectively, included. Transfused patients were younger. At mean fluorescence intensity (MFI) cutoff 500, 36.7% of transfused patients developed de novo HLA class 1 bDSA and 23.3% de novo HLA class 2 bDSA. Overall, de novo HLA class 1 and class 2 antibodies were non-significantly higher in the transfused group (64.7%/55.9%) than in the non-transfused group (46.4% for both, p = 0.200 and p = 0.610, respectively). Risk factors identified included younger age (p < 0.05) and rhesus factor D (RhD) negative status (p = 0.021). The number of shared eplet mismatches was associated with corresponding de novo HLA antibodies (p = 0.02). Conclusions Blood transfusion can be associated with bDSA in paediatric kidney disease, especially with shared blood and kidney donor mismatches. Strategies to avoid sensitisation, such as HLA selection of blood donors, may reduce this risk. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- Open Access
- 15 October 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (2) , 291-303
Human leukocyte antigen sensitization from red cell transfusions: Rate and risk factors in renal and nonrenal patients requiring transfusion
- 15 October 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (2) , 291-303
Open AccessHuman leukocyte antigen sensitization from red cell transfusions: Rate and risk factors in renal and nonrenal patients requiring transfusion
- Open Access
- 29 January 2025
- Published by Wiley in Vox Sanguinis
- Vol. 120 (4) , 374-382
Use of immunoglobulin G homeostatic set point and recovery time in plasmapheresis donor safety monitoring: A retrospective observational cohort study
Background and Objectives: Serum immunoglobulin G (IgG) and total protein are used to monitor plasmapheresis donor safety. However, there is a lack of information from large donor cohorts to determine the best use of these measurements.Materials and Methods: We identified 230,144 plasmapheresis donors making their first donation between 1 July 2020 and 31 March 2024. IgG and total protein were measured prior to the first donation and then annually, following our donor safety monitoring protocol. We considered individuals who had not donated for 12 months to estimate intra‐individual biological variability of IgG. We compared four models to predict which donors would develop IgG < 6 g/L.Results: The IgG reference interval for the cohort was 7.67–15.6 g/L. IgG declines 5%–11% after the age of 45 years. The intra‐individual biological variability of IgG (5.2%) is small, indicating that there is homeostatic set point for individual IgG. IgG is reduced by plasmapheresis but recovers to recruitment level after 12 weeks. When plasma is donated every 2–3 weeks, mean IgG plateaus 1 g/L below recruitment concentration. IgG at recruitment is the best predictor of which donors will have IgG < 6 g/L after a year of donations. Total protein is a low‐value test in this context.Conclusion: Plasmapheresis is safe and sustainable for almost every donor, at the 2‐weekly frequency allowed in Australia. The donors most likely to experience unacceptably low IgG are those with very low recruitment IgG levels. These donors could be recommended 12‐week intervals between donations or other donation types.
- 29 January 2025
- Published by Wiley in Vox Sanguinis
- Vol. 120 (4) , 374-382
Open AccessUse of immunoglobulin G homeostatic set point and recovery time in plasmapheresis donor safety monitoring: A retrospective observational cohort study
Background and Objectives: Serum immunoglobulin G (IgG) and total protein are used to monitor plasmapheresis donor safety. However, there is a lack of information from large donor cohorts to determine the best use of these measurements.Materials and Methods: We identified 230,144 plasmapheresis donors making their first donation between 1 July 2020 and 31 March 2024. IgG and total protein were measured prior to the first donation and then annually, following our donor safety monitoring protocol. We considered individuals who had not donated for 12 months to estimate intra‐individual biological variability of IgG. We compared four models to predict which donors would develop IgG < 6 g/L.Results: The IgG reference interval for the cohort was 7.67–15.6 g/L. IgG declines 5%–11% after the age of 45 years. The intra‐individual biological variability of IgG (5.2%) is small, indicating that there is homeostatic set point for individual IgG. IgG is reduced by plasmapheresis but recovers to recruitment level after 12 weeks. When plasma is donated every 2–3 weeks, mean IgG plateaus 1 g/L below recruitment concentration. IgG at recruitment is the best predictor of which donors will have IgG < 6 g/L after a year of donations. Total protein is a low‐value test in this context.Conclusion: Plasmapheresis is safe and sustainable for almost every donor, at the 2‐weekly frequency allowed in Australia. The donors most likely to experience unacceptably low IgG are those with very low recruitment IgG levels. These donors could be recommended 12‐week intervals between donations or other donation types.